Morgan Stanley
TCRX icon

Morgan Stanley’s TScan Therapeutics TCRX Stock Holding History

Morgan Stanley’s Portfolio TCRX Stock Details TCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$194K Buy
197,891
+24,248
+14% +$25.8K ﹤0.01% 5969
2026
Q1 		$175K Sell
173,643
-52,186
-23% -$55.8K ﹤0.01% 5926
2025
Q4 		$226K Sell
225,829
-621,708
-73% -$900K ﹤0.01% 5886
2025
Q3 		$1.54M Sell
847,537
-5,809
-0.7% -$10.3K ﹤0.01% 4931
2025
Q2 		$1.24M Buy
853,346
+260,376
+44% +$376K ﹤0.01% 4994
2025
Q1 		$818K Buy
592,970
+180,112
+44% +$390K ﹤0.01% 5100
2024
Q4 		$1.26M Buy
412,858
+113,539
+38% +$515K ﹤0.01% 4972
2024
Q3 		$1.49M Buy
299,319
+57,647
+24% +$348K ﹤0.01% 4816
2024
Q2 		$1.41M Buy
241,672
+17,778
+8% +$140K ﹤0.01% 4777
2024
Q1 		$1.78M Sell
223,894
-10,809
-5% -$68K ﹤0.01% 4660
2023
Q4 		$1.37M Sell
234,703
-24,744
-10% -$113K ﹤0.01% 4757
2023
Q3 		$664K Buy
259,447
+150,972
+139% +$352K ﹤0.01% 5026
2023
Q2 		$271K Sell
108,475
-22,844
-17% -$61.3K ﹤0.01% 5510
2023
Q1 		$276K Buy
131,319
+89,144
+211% +$212K ﹤0.01% 5557
2022
Q4 		$65.4K Sell
42,175
-22,395
-35% -$54.9K ﹤0.01% 6170
2022
Q3 		$197K Buy
64,570
+7,481
+13% +$24.5K ﹤0.01% 5733
2022
Q2 		$180K Buy
57,089
+18,013
+46% +$49.3K ﹤0.01% 5956
2022
Q1 		$110K Buy
39,076
+11,672
+43% +$50.5K ﹤0.01% 6251
2021
Q4 		$123K Sell
27,404
-832
-3% -$6.01K ﹤0.01% 6317
2021
Q3 		$235K Buy
+28,236
New +$262K ﹤0.01% 5908

Other funds holding TCRX

LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
DMC
Deer Management Company Larchmont, New York $812M AUM 2.64% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

Morgan Stanley's TCRX Position: Q2 2026 in Review

Morgan Stanley increased its TScan Therapeutics (TCRX) stake by 14% in Q2 2026, buying an estimated $25.8K and bringing the position to 197,891 shares worth $194K. The position accounts for ﹤0.01% of the portfolio, ranked #5969.

Morgan Stanley first reported a position in TCRX in Q3 2021 and has held it in 20 quarters since. The position peaked at $1.78M in Q1 2024. 60 funds tracked by Wall St. Rank hold TCRX as of Q2 2026.

  • Morgan Stanley held 197,891 shares of TScan Therapeutics worth $194K as of Q2 2026.
  • Morgan Stanley bought 24,248 TScan Therapeutics shares in Q2 2026, an estimated $25.8K.
  • TScan Therapeutics made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #5969 holding.
  • Morgan Stanley first reported a position in TScan Therapeutics in Q3 2021 and has held it in 20 quarters since.
  • Morgan Stanley's TScan Therapeutics position peaked at $1.78M in Q1 2024.
  • 60 funds tracked by Wall St. Rank held TScan Therapeutics as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.